Search Results

You are looking at 171 - 180 of 576 items for :

  • Refine by Access: All x
Clear All
Full access


oncology care to patients with cancer and cancer survivors, including addressing unique needs of LGBTQ+ people with cancer, retaining high-value staff during the current landscape, and reducing the toll from cancer treatment-related fatigue and other

Full access


doctor about anything that feels different after the procedure, even years later, especially issues including rash, diarrhea, nausea, vomiting, poor appetite, fatigue, jaundice (yellow coloring of the skin and eyes), joint stiffness, mouth sores, and dry

Full access

Making the Grade: The Impact of Low-Grade Toxicities on Patient Preference for Treatment With Novel Agents

Emily H. Castellanos, Sheau-chiann Chen, Hillary Drexler, and Leora Horn

.79–0.94), adjusted for anticipated benefit and toxicity grades. For example, 32.5% of patients stated they would decline curative intent treatment if grade 2 vomiting were expected versus 10.6% if grade 2 rash were expected. Fatigue also had a strong impact on

Full access

Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation

Jun Gong, Chongkai Wang, Peter P. Lee, Peiguo Chu, and Marwan Fakih

decreased in size. Because of significant fatigue, the patient was transitioned to maintenance 5-FU, leucovorin, and bevacizumab starting from cycle 5. He received an additional 11 cycles of maintenance 5-FU, leucovorin, and bevacizumab (16 cycles overall

Full access

Metastatic Insulinoma: Current Molecular and Cytotoxic Therapeutic Approaches for Metastatic Well-Differentiated panNETs

Iulia Giuroiu and Diane Reidy-Lagunes

.gov identifier: NCT01010126). However, his treatment course was complicated by grade 3 mucositis, grade 2 thrombocytopenia, and grade 2 fatigue, which led to disenrollment from the trial in March 2010 despite a dose reduction. In August 2010, the patient again

Full access

Swedish Version of the Distress Thermometer: Validity Evidence in Patients With Colorectal Cancer

Elisabeth Kenne Sarenmalm, Salmir Nasic, Cecilia Håkanson, Joakim Öhlén, Eva Carlsson, Monica E. Pettersson, and Richard Sawatzky

, cognitive, emotional, and social), 3 symptom subscales (fatigue, pain, nausea/vomiting), and 6 single-item scales (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The QLQ-C30 also generates a global health status based

Full access

Ability to Predict New-Onset Psychological Distress Using Routinely Collected Health Data: A Population-Based Cohort Study of Women Diagnosed With Breast Cancer

Ania Syrowatka, James A. Hanley, Daniala L. Weir, William G. Dixon, Ari N. Meguerditchian, and Robyn Tamblyn

depression. 6 Reasons range from significant overlaps in prodromal symptoms of psychological distress and treatment-related side effects (eg, insomnia and fatigue) to patients' reluctance to disclose psychological distress due to stigma around mental health

Full access

Multidisciplinary Management of Advanced Kidney Cancer

Presented by: Chad A. LaGrange, M. Dror Michaelson, and Colleen H. Tetzlaff

(Figure 1). The patient elected to receive full-dose pazopanib. The dose was reduced from 800 mg/day to 600 mg/day due to fatigue. After 10 months, he developed progressive disease. Preferred subsequent therapy is cabozantinib, nivolumab monotherapy, or

Full access

Comorbidities, Rather Than Older Age, Are Strongly Associated With Higher Utilization of Healthcare in Colorectal Cancer Survivors

Melissa S.Y. Thong, Daniel Boakye, Lina Jansen, Uwe M. Martens, Jenny Chang-Claude, Michael Hoffmeister, Hermann Brenner, and Volker Arndt

Chemotherapy was associated with increased non–CRC-related MS visits in our study, probably because of long-term adverse treatment effects, such as neuropathy or fatigue. These symptoms can persist and have a negative impact on functioning. 43 , 44 Our results

Full access

Associations of Skeletal Muscle With Symptom Burden and Clinical Outcomes in Hospitalized Patients With Advanced Cancer

Emily van Seventer, J. Peter Marquardt, Amelie S. Troschel, Till D. Best, Nora Horick, Chinenye Azoba, Richard Newcomb, Eric J. Roeland, Michael Rosenthal, Christopher P. Bridge, Joseph A. Greer, Areej El-Jawahri, Jennifer Temel, Florian J. Fintelmann, and Ryan D. Nipp

particularly at risk for experiencing high symptom burden and loss of muscle. 16 – 18 Patients with muscle loss often require hospital-level care to address treatment adverse effects and high symptom burden (eg, pain, fatigue, nausea). 19 Notably